Blood Neurofilament Light Chain as a Marker in Substance-Using Populations

Meta-Analysis Finds Elevated Blood NfL in Substance-Using Populations

A systematic review and meta-analysis published on September 15, 2026, in an OpenAlex-indexed venue (OpenAlex W7213350809) reports that individuals who use psychoactive substances have significantly higher blood neurofilament light chain (NfL) levels compared to non-using controls. NfL, a structural protein released into the bloodstream following neuroaxonal injury, is increasingly used as a biomarker in neurology and psychiatry. The meta-analysis, registered with PROSPERO (CRD420251270728), synthesized data from 11 observational studies (16 comparisons) spanning multiple psychoactive substances and control groups. The pooled geometric mean ratio (GMR) of NfL in substance users versus controls was 1.81 (95% CI: 1.49–2.20), indicating a substantial elevation.

Understanding NfL: Mechanism, Specificity, and Context

Blood NfL is a sensitive but non-specific marker of neuroaxonal injury, reflecting general neurobiological burden rather than pinpointing the anatomical source or cause. NfL is released into the bloodstream when axonal damage occurs, regardless of the underlying pathology. In this meta-analysis, the strongest association was observed in alcohol-using populations (GMR = 2.09, 95% CI: 1.62–2.70), but elevated NfL was also seen across studies of other psychoactive substances. Importantly, studies using the highly sensitive single molecule array (SIMOA) assay confirmed the association, though with slightly attenuated effect sizes (GMR = 1.64, 95% CI: 1.41–1.91).

Meta-regression analyses found that studies with higher male representation reported larger effect sizes, while other demographic and methodological moderators were largely nonsignificant. This gender effect may reflect differences in substance use patterns, comorbidities, or biological susceptibility, but causality remains unclear. The review did not identify substantial publication bias, strengthening the validity of the findings.

Implications for Research, Clinical Trials, and Policy

The finding that psychoactive substance use is associated with elevated blood NfL has significant implications for neuroscience research, clinical trial design, and public health. For researchers, NfL offers a minimally invasive biomarker to quantify neuroaxonal injury and monitor neurotoxicity in both classic and novel psychoactive drug studies. However, the non-specificity of NfL limits its utility as a standalone diagnostic tool. It cannot, by itself, distinguish between injury caused by substance use, pre-existing neurological conditions, or other factors such as trauma or infection.

For clinical trials involving psychoactive substances—including those investigating therapeutic uses of psychedelics—NfL may serve as a safety biomarker to monitor for potential neurotoxicity. However, trial protocols must account for confounding variables, including baseline NfL variability and comorbid substance use. Notably, the meta-analysis underscores the need for longitudinal studies to clarify whether elevated NfL reflects reversible or progressive injury, and whether changes in NfL correlate with clinical outcomes.

From a policy perspective, elevated NfL in substance-using populations may inform harm reduction strategies and screening programs, but does not provide a basis for regulatory action or legal claims regarding specific substances. Policymakers should avoid over-interpreting NfL elevations as direct evidence of harm from any single psychoactive agent.

Risks, Limitations, and Unknowns

NfL is a non-specific marker, and elevated levels do not establish causality or localize the site of neuroaxonal injury. The included studies varied in substance type, assay method, and participant characteristics, introducing heterogeneity that could affect the pooled results. While the meta-analysis used robust statistical methods, residual confounding cannot be ruled out. For example, co-use of multiple substances, underlying medical conditions, or unmeasured lifestyle factors may contribute to elevated NfL.

Importantly, the clinical significance of modest NfL elevations in asymptomatic individuals remains uncertain. There is limited evidence linking blood NfL changes to functional neurological outcomes in substance-using populations. Additionally, the gender effect observed in the meta-regression suggests that future studies should stratify by sex and examine potential biological or behavioral moderators. A non-obvious implication is that NfL elevations may reflect cumulative lifetime exposure or acute intoxication, which has consequences for interpreting cross-sectional versus longitudinal data in both research and clinical settings.

Looking Forward: Research Priorities and Clinical Integration

Future research should prioritize longitudinal studies tracking NfL dynamics before, during, and after substance use, ideally alongside neuroimaging and cognitive assessments. Integrating NfL measurement into clinical trials of both recreational and therapeutic psychoactives may help clarify neurotoxicity risks and inform safety monitoring protocols. However, given its non-specificity, NfL should be interpreted in conjunction with other biomarkers and clinical data.

For clinicians and researchers, the key takeaway is that elevated NfL signals increased neurobiological burden in substance-using populations, but its meaning must be contextualized within a broader clinical and research framework. As the field advances, careful methodological design and transparent reporting will be essential to realize the full potential—and recognize the limitations—of NfL as a biomarker in addiction science and psychedelic research.

How we research: This article was written and reviewed by Dr. Alex R. Greene, PhD (Neuroscience), on 2026-09-18. Primary source: OpenAlex W7213350809. PRISMA and PROSPERO registration verified. All clinical and methodological claims are directly sourced from the cited meta-analysis and its registry entry.